Back to Search Start Over

Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes.

Authors :
Mudaliar S
Armstrong DA
Mavian AA
O'Connor-Semmes R
Mydlow PK
Ye J
Hussey EK
Nunez DJ
Henry RR
Dobbins RL
Source :
Diabetes care [Diabetes Care] 2012 Nov; Vol. 35 (11), pp. 2198-200. Date of Electronic Publication: 2012 Sep 25.
Publication Year :
2012

Abstract

Objective: Remogliflozin etabonate (RE), an inhibitor of the sodium-glucose transporter 2, improves glucose profiles in type 2 diabetes. This study assessed safety, tolerability, pharmacokinetics, and pharmacodynamics of RE in subjects with type 1 diabetes.<br />Research Design and Methods: Ten subjects managed with continuous subcutaneous insulin infusion were enrolled. In addition to basal insulin, subjects received five randomized treatments: placebo, prandial insulin, 50 mg RE, 150 mg RE, and mg RE 500.<br />Results: Adverse events and incidence of hypoglycemia with RE did not differ from placebo and prandial insulin groups. RE significantly increased urine glucose excretion and reduced the rise in plasma glucose concentration after oral glucose. RE reduced incremental adjusted weighted mean glucose (0-4 h) values by 42-49 mg/dL and mean glucose (0-10 h) by 52-69 mg/dL.<br />Conclusions: RE can be safely administered with insulin in type 1 diabetes and reduces plasma glucose concentrations compared with placebo.

Details

Language :
English
ISSN :
1935-5548
Volume :
35
Issue :
11
Database :
MEDLINE
Journal :
Diabetes care
Publication Type :
Academic Journal
Accession number :
23011728
Full Text :
https://doi.org/10.2337/dc12-0508